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Abstract
Biochemical and biological properties of glycoconjugates are strongly determined by the specifi c structure of its glycan parts. Glycosylation, the 
covalent attachment of sugars to proteins and lipids, is very complex and highly-coordinated process involving > 250 gene products. Defi ciency of 
glycosylation enzymes or transporters results in impaired glycosylation, and consequently pathological modulation of many physiological processes. 
Inborn defects of glycosylation enzymes, caused by the specifi c mutations, lead to the development of rare, but severe diseases – congenital disor-
ders of glycosylation (CDGs). Up today, there are more than 45 known CDGs. Their clinical manifestations range from very mild to extremely severe 
(even lethal) and unfortunately, only three of them can be eff ectively treated nowadays. CDG symptoms highly vary, though some are common for 
several CDG types but also for other unrelated diseases, especially neurological ones, leaving the possibility that many CDGs cases are under- or mis-
diagnosed. Glycan analysis of serum transferrin (by isoelectric focusing or more sophisticated methods, such as HPLC (high-performance liquid chro-
matography) or MALDI (matrix-assisted laser desorption/ionization)) or serum N-glycans (by MS), enzyme activity assays and DNA sequence analysis 
are the most frequently used methods for CDG screening and identifi cation, since no specifi c tests are available yet. In this review we summarize the 
current knowledge on the clinical, biochemical and genetic characteristic of distinct CDGs, as well as existing diagnostic and therapeutic procedures, 
aiming to contribute to the awareness on the existence of these rare diseases and encourage the eff orts to elucidate its genetic background, improve 
diagnostics and develop new strategies for their treatment.
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Introduction
Glycans (i.e. carbohydrates or sugars) can be cova-
lently linked to the proteins or lipids in the process 
called glycosylation, thus forming diff erent types 
of glycoconjugates (glycoproteins, glycolipids, gly-
cosylphosphatidylinositol (GPI) anchors or proteo-
glycans). The glycan parts of glycoconjugates con-
tribute to diverse physical, biochemical and bio-
logical properties of glycoconjugates, ranging 
from the resistance to protease degradation and 
localization in the cell, to the regulation of immune 
response and metastasis spreading (1-3). Therefore 
it is not surprising that changes of glycosylation 
are related to many medical problems. Glycosyla-
tion of both proteins and lipids occurs in endoplas-
mic reticulum (ER) and/or Golgi apparatus (GA), 
depending on the specifi c type of glycosylation. 
Depending on the linkage type, through which 
glycans are bound to the protein part, there are 
two kinds of protein glycosylaton: N- and O-glyco-
sylation. The fi rst steps of N-glycosylation process 
involve assembling of a lipid-linked oligosaccha-
ride (LLO) precursor. That process starts at the cy-
toplasmic side of the ER and continues on the lu-
minal side of the ER after the fl ipping of the grow-
ing precursor across the membrane bilayer by the 
mechanism which is not yet fully understood. The 
transfer of completed LLO precursor onto amino-
group of asparagine residue in Asn-X-Ser/Thr se-
quon of the nascently translated polypeptide is 
catalyzed by oligosaccharyltransferase. Addition-
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al remodeling of the glycans by assembly and pro-
cessing reactions catalyzed by numerous glycosyl-
transferases and glycosidases continues in the lu-
men of ER and GA (4). O-glycosylation, attachment 
of glycans to the hydroxyl group of threonine or 
serine moieties of the proteins, does not comprise 
processing, only assembly, which mainly occurs in 
the Golgi apparatus. Diverse and complex glycan 
structures of glycoconjugates are therefore the 
outcome of the coordinated reactions of glycosyl-
transferases, glycosidases, nucleotide-sugar-spe-
cifi c transporters, altogether, more than 250 gene 
products. Gene mutations can cause defects of 
these proteins resulting in inborn errors of metab-
olism, characterized by defi cient or reduced glyco-
sylation and known as congenital disorders of gly-
cosylation (CDGs).
Congenital disorders of glycosylation
Since 1980, when the fi rst N-glycosylation defect 
was described and characterized (5) over 45 types 
of CDGs have been recognized. Although very 
rare, CDGs are the most rapidly expanding group 
among the currently known 3000 monogenetic 
inherited diseases. All known CDGs have a reces-
sive inheritance except EXT1/EXT2-CDG which is 
dominantly inherited and MGAT1-CDG which is X-
linked (6).
CDGs were fi rst classifi ed as type I (CDG-I) related 
to the disrupted synthesis of the lipid-linked oligo-
saccharide precursor and type II (CDG-II) involving 
malfunctioning processing/assembly of the pro-
tein-bound oligosaccharide chain (7). However, 
since 2009, most of the researchers use a novel no-
menclature based on the name of the aff ected 
gene (e.g. CDG-Ia = PMM2-CDG, CDG-Ib = MPI-
CDG) (8). According to the novel classifi cation, 
CDGs are divided into 4 categories as defects of:
protein N-glycosylation (16 types of CDGs),• 
protein O-glycosylation (8 types of CDGs),• 
lipid glycosylation and glycosylphosphatidylinosi-• 
tol anchor glycosylation (3 types of CDGs), and
defects in multiple glycosylation pathways and • 
in other pathways (17 types of CDGs) (6).
In addition, several CDGs of so far unknown etiol-
ogy (CDG-x) have been recognized. CDG symp-
toms highly vary, but some are common for sever-
al CDG types, such as psychomotor retardation, 
failure to thrive, coagulopathies, dysmorphic fea-
tures, seizures and stroke-like episodes (9,10). Clini-
cal manifestation of CDGs ranges from very mild 
to extremely severe (literately, all organs can be af-
fected). The resemblance to some other diseases, 
especially neurological ones and the physicians’ 
unawareness of the existence of these diseases, 
are the main reasons why CDGs still remain under- 
or misdiagnosed. In addition, the population stud-
ies on the frequency of the mutations causing 
CDGs are still scarce. Based on the determined fre-
quency of heterozygotes, the estimated incidence 
of homozygotes for certain mutations are as high 
as 1:20,000, suggesting the existence of much 
higher number of cases than documented (10). In 
this review, we will provide an overview of the 
characteristics of currently known CDGs, classifi ed 
according to novel nomenclature (8) (with the old 
one given in italics in brackets), as well as biochem-
ical and genetic diagnostic methods and thera-
peutic approaches for the treatment of these rare 
diseases. Due to the space limitation, this review 
describes only CDGs’ types present in more than 
few patients or characterized by unique pheno-
type.
Defects of protein N-glycosylation
Sixteen defects of protein N-glycosylation have 
been detected so far: 14 assembly defects and 2 
processing defects, classifi ed according to the old 
nomenclature as CDG type I (CDG-I) and CDG type 
II (CDG-II), respectively.
PMM2-CDG (CDG-Ia)
PMM2 gene (NG-009209.1), mapped on chromo-
some 16p13, encodes phosphomannomutase (NP-
000294.1), an enzyme that transforms mannose-6-
phosphate into mannose-1-phosphate (Figure 1) 
(11). Some of the mutations in PMM2 gene cause 
PMM2-CDG (CDG-Ia, OMIM≠212065), the most 
prevalent type of CDGs detected in more than 700 
patients worldwide (12). Molecular analysis re-
vealed a large number (> 100) of mutations all over 
8 PMM2 exons, but the mutational hot spots were 
detected in exons 5 and 8 (13,14). The most fre-
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quent mutations known by now, p.R141H and p.
F119L, both caused by a single base mutation, 
c.422G>A (rs28936415) and c.357C>A (rs80338701), 
respectively (15), are located in exon 5. p.R141H has 
never been observed in the homozygous form, 
thus being considered lethal (15). Interestingly, 
PMM2-CDG patients (heterozygotes for p.R141H) 
have 0-10% of normal PMM2 activity in fi broblasts 
and leukocytes while their asymptomatic parents, 
who are also heterozygotes have approximately 
50% residual activity of PMM2 enzyme. It seems 
that compound heterozygosity for p.R141H and 
some other mutations in PMM2 gene (e.g. p.F119L) 
is responsible for the decreased PMM2 activity, in-
adequate for normal glycosylation. Mutation p.
F119L itself is very mild, but mentioned compound 
heterozygosity for p.R141H and p.F119L mutations 
is the most frequent genotype of CDG-Ia, account-
ing for 27% of 249 patients from 23 countries (16). 
Numerous other mutations all over the PMM2 gene 
also come in diff erent combinations, and the re-
sulting compound heterozygosity leads to more 
or less severe manifestations of PMM2-CDG.
Clinical presentation and course of PMM2-CDG are 
highly variable, and range from death in the early 
childhood due to severe infections, liver insuffi  -
ciency, or cardiomyopathy (10,17) to mildly aff ect-
ed adults (18). When manifested at birth PMM2-
CDG is usually severe multi-organ disease charac-
terized by strong dysfunction of central and pe-
ripheral nervous system (19,20). Common features, 
although not necessarily present in neonates with 
PMM2-CDG, are inverted nipples, unusual subcu-
taneous fat, thin upper lip and often muscular hy-
potonia (21).
MPI-CDG (CDG-Ib)
MPI-CDG (OMIM≠602579) arises due to the defi -
ciency in mannosephosphate isomerase (MPI, NP-
002426.1), also known as phosphomannose 
isomerase (PMI), an enzyme which catalyzes the 
formation of mannose-6-phosphate from fruc-
tose-6-phosphate (Figure 1) (22). It is encoded by 
MPI gene (NG_008921.1), in which eighteen muta-
tions have been detected by now; 15 point muta-
tions, one splicing defect and two frameshift caus-
ing mutations.
Clinical presentation of this disease is unique 
among CDGs due to the fact that neurological 
symptoms are usually absent. Gastrointestinal 
tract and the liver are mainly aff ected and symp-
toms usually comprise vomiting, diarrhea, gastro-
intestinal bleeding, protein-losing enteropathy 
and hepatomegaly. Additionally, in more severe 
cases, hypoglycemia, coagulopathy, as well as 
thrombotic events (protein C and S defi ciency, low 
antithrombin III levels) can be observed. Interest-
ingly, MPI-CDG is one of a few CDGs which can be 
eff ectively treated by oral administration of man-
nose. Since it is potentially lethal, it is of utmost im-
portance to examine patients with inexplicable 
coagulopathies, intestinal protein loss or hypogly-
cemia for this disorder.
ALG6-CDG (CDG-Ic)
The second most frequent type of CDGs is ALG6-
CDG (OMIM #603147), clinically characterized by 
psychomotor retardation, dysmorphic features, 
muscular hypotonia, seizures and epilepsy (23-26). 
Psychomotor development is less retarded than in 
PMM2-CDG and ALG6-CDG could be in general 
considered as a milder type of CDG. It is caused by 
mutations in ALG6 gene (NG_008925) that encodes 
dolichyl-P-glucose: mannose9-N-acetyl glu-
cosamine2-pyrophosphate-dolichyl (Dol-P-
Glc:Man9GlcNAc2-P-P-Dol) α-1,3 glucosyltrans-
ferase (NP_037471.2), an enzyme that participates 
in the formation of the lipid-linked oligosaccharide 
precursor of N-linked glycosylation (Figure 1) (27-
29). At least 30 patients were identifi ed worldwide 
(12), which were aff ected by one of twenty one 
mutations described so far; sixteen point muta-
tions, one insertion and four deletions (including a 
large deletion enclosing the complete ALG6 gene). 
The most common mutation in ALG6 gene causing 
ALG6-CDG is c.998C>T resulting in p.A333V substi-
tution (23,27). However, recent case of 11-year old 
Saudi Arabian boy with dilated cardiomyopathy 
which revealed a novel c.482A>G (p.Y161C) muta-
tion, suggests that CDG should be considered in 
the diff erential diagnosis of unexplained cardio-
myopathy (30).
Two point mutations c.391T>C in exon 5 and 
c.911T>C in exon 10 resulting in p.Y131H and p.
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F304S, respectively, although assumed being sin-
gle nucleotide polymorphisms (rs35383149 and 
rs17856039) (31,32) are particularly interesting. It 
was shown that p.F304S polymorphism may exac-
erbate the clinical outcome of other CDGs, espe-
cially in severely aff ected patients (33). For the p.
Y131H substitution it is still unclear whether the 
homozygous form c.391C/C is suffi  cient to cause 
the disease or some additional genetic alteration 
has to be present (31). We have recently shown 
that the frequency of heterozygotes in Croatian 
population is 3 times higher (6.7%) than in US pop-
ulation (2.1%), the only one screened for p.Y131H 
until now (31,34). The obtained results suggest the 
incidence of homozygotes for p.Y131H 1 in 1000 in 
Croatian population, but up today no patient with 
ALG6-CDG has been detected in Croatia (34).
ALG3-CDG (CDG-Id)
ALG3-CDG (OMIM#601110) is caused by a defect of 
mannosyltransferase VI, an enzyme involved in 
completing of the LLO structure Glc3Man9GlcNAc2-
P-P-Dol (NP_001006942.1) (Figure 1). All six patients 
described so far have displayed a slowly progres-
sive encephalopathy with microcephaly, severe psy-
chomotor retardation and epileptic seizures (35).
ALG12-CDG (CDG-Ig)
ALG12-CDG (OMIM #607143) is caused by a defect 
of another mannosyltransferase participating in fi -
FIGURE 1. N-linked glycan biosynthetic pathway and defects of protein N-glycosylation.
Mannose-6-phosphate (Man-6-P) is generated from the fructose-6-phosphate (Fru-6-P) and converted to mannose-1-phosphate 
(Man-1-P). Activated mannose (Man) and activated N-acetylglucosamine (GlcNAc) are used to build the lipid-linked oligosaccharide 
(LLO) precursor, which is assembled on the activated dolichol on the endoplasmic reticulum (ER) membrane and fl ipped into the ER 
lumen. Further extension yields oligosaccharide consisting of 2 GlcNAc, 9 Man and 3 glucoses (Glc) which is transferred onto aspar-
agines residues of the polypeptide. Additional trimming and processing of oligosaccharide continues in the Golgi apparatus (GA). 
CDGs are named according to novel nomenclature, with the abbreviated old names give in brackets. Fru – fructose; Man – mannose; 
GDP – guanidine diphosphate; UDP – uridine diphosphate; OST – oligosaccharyltransferase.
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nalizing of LLO - mannosyltransferase VIII 
(NP_077010.1) (Figure 1) (36). All six patients de-
scribed so far, exhibited various combination of 
common CDG symptoms.
ALG8-CDG (CDG-Ih)
ALG8-CDG (OMIM#608104), caused by the defi -
ciency of glucosyltransferase II (NP_001007028.1), 
participating in one of the last steps of LLO forma-
tion (Figure 1), was recognized in fi ve patients. 
Three of them exhibited severe clinical picture 
with multiorgan failure, while in two others milder 
symptoms were observed (37).
ALG1-CDG (CDG-Ik)
ALG1-CDG (OMIM #608540) is caused by the defi -
ciency of mannosyltransferase (NP_061982.3) due 
to the mutations in ALG1 gene (NG_009202.1). This 
enzyme catalyses addition of the fi rst mannose 
during formation of the pyrophosphate-linked 
seven sugar glycan structure (Man5GlcNAc2-P-P-
Dol) (Figure 1). Up today, it was diagnosed in four 
patients with epilepsy, cardiomyopathy, hypogo-
nadism and severe psychomotor retardation (38).
RFT1-CDG (CDG-In)
RFT1-CDG (OMIM#612015), the fi rst CDG recog-
nized to be associated with sensorineural deaf-
ness, was described in six patients so far. RFT1 
(NP_443091.1), a fl ippase encoded by the RFT1 
gene (NG_009203.1), is involved in the transfer of 
Man5GlcNAc2-P-P-Dol from the cytoplasmic to the 
luminal side of the endoplasmic reticulum (Figure 
1) (39).
In addition, there are three other CDGs related to 
the defects of protein N-glycosylation: TUSC3-
CDG, MGAT1-CDG and MGAT2-CDG (CDG-IIa) (Fig. 
1). TUSC3-CDG and MGAT1-CDG are related to the 
defects in the subunits of the oligosaccharyltrans-
ferase complex, and both are manifested as non-
syndromic mental retardation. Unlike the other 
known CDGs, MGAT1-CDG is X-linked disorder. 
MGAT2-CDG refl ects impaired N-acetylglucosami-
nyltransferase II, an enzyme involved in N-glycan 
processing.
Defects of protein O-glycosylation
CDGs related to the defects of protein O-glycosy-
lation comprise six disorders: EXT1/EXT2-CDG and 
B4GALT/-CDG (defects in the synthesis of O-xylo-
sylglycans), GALNT3-CDG (defect in the synthesis 
of O-N-acetylgalactosaminylglycans), SLC35D1-CDG 
(defect in the O-xylosyl/N-acetylgalactosaminyl/
glycans), POMT1/ POMT2-CDG and POMGNT-CDG 
(defects in the synthesis of O-mannosylglycan core 
previously known as Walker-Warburg syndrome 
and muscle-eye-brain disorder, respectively) and 
SCDO3-CDG and B3GALTL-CDG (defects in the syn-
thesis of O-fucosylglycans). EXT1/EXT2-CDG will 
be briefl y discussed because of its characteristic 
features distinguished from other CDG types and 
its prevalence.
EXT1/EXT2-CDG
EXT1/EXT2-CDG (OMIM#133700/133701), also 
called hereditary multiple osteochondroma (MO) 
is the only CDG with autosomal dominant inheri-
tance. It is a monosystemic CDG characterized by 
formation of benign osteochondromas at the ends 
of long bones in childhood, which, in some cases, 
can become malignant lesions resulting in osteo-
sarcomas and chondrosarcomas in adult age. He-
reditary multiple osteochondromas are usually 
caused by various mutations in EXT1 or EXT2 genes 
or in other homologous EXTL genes, while large 
genomic deletions in EXT1 or EXT2 are responsible 
for up to 8% of the cases (40). All members of this 
multigene family encode gylcosyltransferases in-
volved in the adhesion and/or polymerization of 
heparin sulfate (HS) chains at HS proteoglycans. 
EXT1 and EXT2 form heterooligomeric protein 
complex, which in GA catalyses addition of N-
acetylglucosamine and glucuronic acid, thus elon-
gating HS-chains. With more than 900 aff ected pa-
tients (41), EXT1/EXT2-CDG represents one of the 
most frequent CDGs, and according to the novel 
nomenclature it signifi cantly increased the total 
number of CDGs previously estimated to be about 
1000. In addition, the estimated incidence of 1/50 
000 in Western population (42,43), is expected to 
be an underestimation because of many patients 
with very mild symptoms that are often not identi-
fi ed.
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Defects of glycosphingolipid and 
GPI-anchor glycosylation
This group of defects comprises tree disorders: 
PIGM-CDG, PIGMV-CDG (caused by the defects of 
the fi rst and the second mannosyl-transferases in 
the GPI-anchor biosynthesis pathway, respective-
ly) and SIA9-CDG (Amish infantile epilepsy) caused 
by the defect of GM3 synthase, a sialyltransferase, 
which catalyses the initial step in the biosynthesis 
of complex gangliosides.
Defects of multiple glycosylation and 
other pathways
Many of the defects which were previously includ-
ed in CDG nomenclature are in fact not limited to 
the N- or O-glycosylation pathways, and their 
manifestations are due to the defects in other 
pathways involved in carbohydrate metabolism. 
CMP-sialic acid transporter (SLC35A1) defi ciency of 
which was related to CDG-IIf (OMIM#603585) and 
the GDP-fucose transporter (SLC35C1) (previously 
being related to CDG-IIc, OMIM#266265) are ex-
amples of the proteins aff ecting multiple glycosyla-
tion pathways. DK1-CDG (CDG-Im) (OMIM#610768) 
is also a good example, because dolichol kinase 1 
provides a substrate for N- and O-linked glycans, 
GPI anchors and C- and O-mannosylation and in 
that way impairs multiple pathways (44). Up today, 
defects of multiple glycosylation and other path-
ways comprise 17 defects (8), and some of them 
are briefl y described in the next sessions.
COG-CDG
Conserved oligomeric Golgi (COG) complex is a 
large, eight-subunits (Cog1-Cog8) complex which 
plays a key role in protein transport between ER 
and Golgi and within Golgi (10). Complex is orga-
nized into two substructures; lobe A contains Cog 
2-4 and lobe B Cog 5-7 (45,46), while Cog1 and 
Cog8 bridge those lobes. Six COG-CDG types in 10 
patients have been identifi ed so far (47,48). In addi-
tion, cutis laxa syndrome, a rare skin disorder char-
acterized by wrinkled skin due to defective syn-
thesis of elastic fi bers and other proteins of the ex-
tracellular matrix, has been described as COG7-
CDG (OMIM#608779) (49). Common features of 
COG-CDGs are dysmorphy, hypotonia, feeding 
problems, growth retardation and cerebral atro-
phy. COG complex is probably not only involved in 
glycosylation but also in other cellular functions, 
so it was proposed the COG defects to be called 
the ˝CDG-plus˝ (12).
ATP6V0A2-CDG (OMIM#611716)
This disorder could be considered as another 
˝CDG-plus˝ defect. Although laboratory fi ndings of 
type 2 pattern on transferrin isoelectrofocusing 
(Tf-IEF), abnormal isoelectrofocusing of apolipo-
protein C-III (apoC-III), and abnormal mass spec-
trometry of glycans of total serum proteins could 
be ascribed to the classical CDG type II caused by 
defects of enzymes involved in glycan processing 
(50,51), the cause of glycosylation disturbance lies 
in defects of α-subunit of the vesicular ATPase H+-
pump. It seems that disturbed H+ concentration in 
vesicules aff ects proper processing of glycans. All 
patients have generalized cutis laxa at birth, but 
ophtalmological abnormalities and delayed motor 
development that improves with age were also 
described (49).
SLC35C1-CDG (CDG-IIc)
This disease (OMIM#266265), also known as Leu-
kocyte Adhesion Defi ciency type II (LAD II) syn-
drome (CDG-IIc), is caused by defective GDP-fu-
cose transporter (SLC35C1; NG_009875.1; 
NP_060859.4), which leads to the lack of fucosylat-
ed selectin ligands and, consequently, to the de-
velopmental defects and immunodefi ciency (52). 
Patients with SLC35C1-CDG also exhibit strong 
mental and growth retardation.
B4GALT1-CDG (CDG-IId)
B4GALT1-CDG (OMIM 607091) is delineated to a 
defi ciency of β1,4-galactosyltransferase 
(E.C.2.4.1.38) (53). Typical clinical presentations are 
Dandy-Walker malformation and myopathy. MAL-
DI analysis of transferrin N-linked glycans revealed 
the presence of species lacking both the terminal 
sialic acids and galactose residues (54).
Laboratory diagnostics
Because of high variety of CDG symptoms and the 
resemblance to other diseases, diagnosis of CDG is 
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very demanding. Thus, a suspicion on CDG should 
arise in a case of any unexplained neurological 
syndrome, particularly when associated with other 
organ disease, as well as in any unexplained syn-
drome without obvious neurological symptoms. 
Therefore, clinical features such as syndromic fat 
pads and/or inverted nipples, chronic diarrhea, liv-
er fi brosis, ichtiosis syndrome, diff erent neurosyn-
domatic conditions (e.g. cataract, sensorineural 
deafness, radio-ulnar synostosis, recurrent infec-
tions), syndromic cardiomyopathy are for certain 
the conditions in which suspicion on CDG should 
arise (6). In that sense, laboratory analysis could be 
very helpful, although no specifi c tests are avail-
able yet. In general, four approaches can be ap-
plied: glycans analyses, measurements of enzyme 
activities and metabolites, classical biochemical 
analyses, and molecular diagnostics. At the mo-
ment, there is no algorithm recommended by any 
professional organization, and majority of the re-
ported studies and case reports are outcomes of 
personal and scientifi c approach of physicians, 
usually performed in collaboration with the scien-
tifi c groups focused on CDGs. However, according 
to Jaeken (12), some general guidelines can be 
proposed (Figure 2). The fi rst step in laboratory di-
agnostics should unquestionably be isoelectric fo-
cusing (IEF) of serum transferrin (Tf) which pro-
vides valuable data for diagnostic of CDGs caused 
by impaired N-glycosylation. If the obtained pat-
tern is abnormal, possible other causes e.g. trans-
ferrin mutants, galactosemia or hereditary fruc-
tose intolerance should be excluded. Depending 
on the obtained pattern (type 1 – CDG-Ix or type 2 
– CDG-IIx) further analyses should be performed. 
In the case of Tf IEF type 1 pattern, enzymatic ac-
tivity of PMM2 and MIP in fi broblasts or leukocytes 
should be determined. If their activities are nor-
mal, the analysis of dolichol-linked oligosaccharide 
(LLO) should be the next step. Higher quantity of 
glycan intermediate(s) implies measurement of 
particular enzyme activity or mutation analyses. If 
Tf IEF has showed type 2 pattern, direct analysis of 
transferrin glycans and IEF of apolipoprotein C-III 
FIGURE 2. Schematic illustration of the strategy for CDG laboratory diagnostics (for N-glycosylation, core 1 mucin-type O-glycosyla-
tion and combined N- and O-glycosylation disorders). IEF – isolectric focusing; Tf – transferrin, ApoC-III apolipoprotein C-III).
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should be performed. The fi nding of specifi c trans-
ferrin glycans profi les could give a clue on im-
paired enzyme, but it usually results reveal just a 
reduced sialylation or galactosylation. In these cas-
es, further steps in laboratory diagnostics should 
be chosen in accordance with specifi c clinical man-
ifestations. However, in some CDGs in which Tf IEF 
pattern is normal, as well as Apo C-III IEF pattern, 
mutation analyses remain the only choice.
Glycan analysis
All CDGs are associated with at least in some ex-
tent by changes of glycosylation. This is why the 
analyses of glycans emerge as the most promising 
screening approach. Yet, lack of a reliable, user 
friendly screening method, which could detect 
specifi c glycosylation changes of particular CDG, 
implies the use of some less specifi c, but still use-
ful approaches.
The simplest and still wildly used methods for CDG 
screening are isoelectric focusing (IEF) of transfer-
rin (Tf) and apolipoprotein C-III (ApoC-III) for N- 
and O-glycan synthesis defects, respectively. Plas-
ma transferrin usually carries 2 complex-type bian-
tennary N-glycans with terminal sialic acids (usual-
ly 4) (Figure 3). Since terminal residues and the 
branching of N-glycans are variable, several iso-
forms of transferrin can be distinguished in healthy 
individuals: tetrasialo-transferrin as a dominant 
fraction and small amounts of mono-, di-, tri-, pen-
ta- and occasionally hexasialotransferrins. ApoC-III 
is a plasma protein containing one core 1 mucin-
type O-glycan. Three isoforms of ApoC-III can be 
distinguished, ApoC-III0, ApoC-III1, and ApoC-III2, 
for which the isoform number, as in transferrin, is 
the number of sialic acid residues attached to the 
core 1 mucin-type O-glycan. Because sialic acid 
has a negative charge, the IEF patterns of hyposia-
lylated transferrin and ApoC-III show a cathodal 
shift that can be caused either by structural glycan 
changes or by a diff erent number of glycans. Thus, 
CDG type I is associated with an increase of asialo- 
and disialotransferrin bands, while CDG type II 
shows an increase of mono and/or trisialotransfer-
rin. However, some other conditions, such as un-
controlled galactosaemia, fructose intolerance and 
alcoholism, can also be associated with altered 
transferrin glycosylation. Additionally, several 
transferrin gene polymorphisms result in a shifted 
IEF pattern, caused by the diff erences in the trans-
ferrin aminoacid composition (55,56). Furthermore, 
some CDG types cannot be identifi ed by transfer-
rin IEF analysis because in some of them transfer-
rin sialylation is not altered e.g. defi ciency of GLS1 
(CDG-IIb), SLC35C1 (CDG-IIc), one of the two Golgi 
GDP-fucose transporters, and TUSC3-CDG. Finally, 
Ctrl
1 2 3
CDG-I CDG-II
pentasialo-Tf
tetrasialo-Tf
trisialo-Tf
disialo-Tf
monosialo-Tf
asialo-Tf
+
–
FIGURE 3. Schematic illustration of transferrin isoforms. Oligosacharrides of normal transferrin (Tf) have most usually four sialic acids 
(tetrasialotransferrin) (Ctrl - control, line 1), but in CDG patients the IEF of serum transferrin reveals additional bands as results of dif-
ferent structural alterations. In CDG type I patients shows abnormal pattern of disialo- and asialotransferrin (CDG-I, line 2). In CDG-II 
patients there are combinations of elevated asialo-, disialo, trisialo and monosialo-Tf fractions (CDG-type II, line 3). Structural illustra-
tions of the major typical isoforms are given on the right side of the picture.
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IEF is laborious, time-consuming technique, and 
not suitable for automation or accurate quantifi ca-
tion, so during last two decades high-performance 
liquid chromatography (HPLC) (57) and capillary 
zone electrophoresis (CZE) (58) have been applied 
for diagnostics of CDGs. They enabled detection 
of altered and even abnormal patterns, which 
might be missed by transferrin IEF (59), though 
some disadvantages such as column cost and fre-
quent and complex column regeneration are still 
present. Additional improvement of CDG diagnos-
tics was achieved by the employment of mass 
spectrometric (MS) analyses (54,60,61). Because of 
high specifi city and sensitivity of MS, and possibil-
ity to be fully automated, diff erent kinds of MS 
found the application in CDG diagnostics, e.g. ESI-
MS (electrospray ionization MS) of transferrin (62), 
MALDI-TOF MS (matrix-assisted laser desorption/
ionization time-of-fl ight MS) of transferrin and α-1-
antitrypsin (63) as well as isolated serum N-linked 
(64) and O-linked glycans (65) and its variation - 
SELDI-TOF-MS (surface-enhanced laser desorp-
tion/ionization TOF MS) (66). Next generation of 
glycan analysis techniques will provide new op-
portunities for identifi cation of novel glycosylation 
defects, especially those which could not be iden-
tifi ed by classical methods.
Measurements of enzyme activities and metabolites
Impaired glycosylation is a result of defi cient or ab-
sent enzyme or transporter activity, thus direct 
measurement of these parameters represents the 
most accurate parameters for CDGs diagnostics. 
Unfortunately, availability of these methods is lim-
ited, and the analyses can be performed in only 
few laboratories in the world. Yet, measurement of 
phosphomannomutase 2 (PMM2) activity in fi bro-
blasts or leukocytes should be the fi rst choice 
when CDG is suspected, since PMM2-CDG is the 
most frequent CDG. In the case of solely hepato-
intestinal clinical symptoms, mannosephosphate 
isomerase (MPI) measurements should be per-
formed. Normal activities of the mentioned en-
zymes indicate further analysis of the lipid-linked 
oligosaccharides (LLO) in fi broblasts or other as-
says to identify known or unknown CDG defect.
Many CDGs are characterized by accumulation of 
the specifi c intermediate structures, mainly sub-
strates of the defi cient enzyme in fi broblasts (e.g. 
Glc1Man9GlcNAc2-P-P-Dol) in ALG8-CDG (37), 
Man5GlcNAc2-P-P-Dol in RFT1-CDG (39), Glc1Man9-
GlcNAc2-P-P-Dol in ALG1-CDG (67), or serum (e.g. 
lactosylceramide in SIAT9-CDG (68).
Biochemical analysis
There are also some standard biochemical tests 
which can contribute to the diagnostics of particu-
lar CDGs. Thus, low plasma cholesterol concentra-
tion and cholinesterase activity with proteinuria 
are common characteristics of PMM2-CDG. MPI-
CDG is usually associated with high aminotrans-
ferases activities (24), while CDGs previously classi-
fi ed as type II are characterized by increased as-
partate aminotransferase (AST) and normal ala-
nine aminotransferase (ALT) activity but CDGs 
type-I are not (69). PIGV is characterized by hyper-
posphatasia (70), while high plasma transferrin 
concentration and thrombocytopenia have been 
also seen in various cases (20). All these fi nding are 
not surprising since many proteins, especially 
membrane and secreted ones are glycosylated 
and glycans highly aff ect their structure and con-
sequently function, as well as localization and se-
cretion.
Molecular diagnostics
Molecular basis of most of all known CDGs has 
been elucidated. In many cases, not only one, two 
or several, but over 100 mutations are known to be 
related to particular CDG (e.g. in PMM2 gene). Mu-
tations can be identifi ed by simple single-strand 
conformational polymorphism analysis (SSCP) 
(71,72), restriction fragment length polymorphism 
(RFLP) (32), real time-polymerase chain reaction 
(PCR) (34), and DNA sequencing (73,74). Compound 
heterozygous or homozygous mutations in the 
coding sequence, but also in promoters, introns 
and splice junctions, as well as deletions of a whole 
region, can be confi rmed at the genomic level. In 
addition, in some cases sequencing of the entire 
gene including all exons, introns and promoters is 
required. Thus, it is obvious that molecular diag-
nostic is valuable approach for a confi rmation of 
the presence of the mutation(s) in the particular 
gene(s), but primarily when suspicion on CDG is 
established based on clinical symptoms and other 
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laboratory analyses. Even then, several suspected 
genes have to be analyzed to identify and charac-
terize mutation(s) which cause the impaired pro-
tein/enzyme functionality and consequently the 
disease. Genetic testing approach can be also ap-
plied for screening for the mutation carriers in the 
population studies. This is why the development 
of novel, cheap, fast and user friendly screening 
methods, which can be applied on small quantity 
of sample, is of utmost importance (75,76).
Prenatal diagnosis
Prenatal diagnostics of CDGs is also available and 
it can be performed in few genetic centers in Eu-
rope and USA, especially for the individuals com-
ing from the families with higher risk for CDGs. 
However, until today, prenatal diagnostics has 
principally been applied in the cases of the suspi-
cion on PPM2-CDG, although it can be performed 
for some other CDGs on the request, but only in 
the research laboratories.
If both parents have already been identifi ed as car-
riers of a recessive gene involved in CDG pathway, 
chorionic villous sampling or amniocentesis should 
be off ered. Prenatal diagnostics can be performed 
by analyzing the activity of the particular enzyme 
in fi broblasts, leukocytes or lymphocytes of the 
proband or in the leukocytes of the parents, or 
screening for mutations in the specifi c gene (77). It 
is worth to point out that prenatal diagnoses are 
also made according to CDG subtype. PMM2-CDG, 
defi ciency of phosphomannomutase 2, can also 
be detected in cultured trophoblasts and amnio-
cytes from the aff ected fetus. However, prenatal 
diagnosis by enzyme assay can give false positive 
results because of the low values of the enzyme in 
poorly growing amniocytes when the fetus is not 
aff ected. Therefore, prenatal testing should only 
be off ered to the families where mutations in the 
PMM2 gene are known, since DNA analysis is the 
most reliable method. It is important to know that 
prenatal diagnostics for PMM2-CDG cannot be 
performed by Tf IEF or any other assay that would 
determine the glycosylation of proteins in the fe-
tus (78).
Due to the severity of the disease, prenatal diag-
nostic services based on combined mutation and 
linkage analysis with polymorphic markers are of-
ten required (79,80).
Therapy
The therapy for only three (MPI-CDG (CDG-Ib), 
SLC35C1-CDG (CDG-IIc) and PIGM-CDG) of almost 
50 known CDG defects is available so far. Yet, lot of 
eff orts is putting in mouse models which were 
shown to be very useful not only in the studies of 
molecular basis of these diseases (21,81), but also 
in the therapeutic studies (82).
MPI-CDG (CDG-Ib)
Defect of mannosephosphate isomerase which 
blocks the endogenous mannose formation from 
glucose (Figure 2), can be overcome by oral admin-
istration of mannose (83). Oral mannose supply 
bypasses the enzymatic block using alternative 
way catalysed by hexokinase (Figure 4) and leads 
to the signifi cant metabolic normalization and dis-
appearance of symptoms. With such therapy pa-
tients usually can live normally. If oral intake of 
mannose is not possible, mannose should be ap-
plied intravenously, yet life-threatening central 
nervous system disturbances can occur, probably 
because of intracellular energy failure. Clinical 
symptoms of such energy defi ciency should be 
treated early and aggressively (84).
Glucose Mannose
Mannose-6-P Mannose-1-P GDP-Mannose
Lactate
Fructose-6-P
Endoplasmic
reticulum
FIGURE 4. Mannose metabolic pathway. Mannose-6-phosphate 
(Man-6-P) is mainly generated from fructose-6-phosphate (Fru-
6-P) by the action of mannosephosphate isomerase (MPI), or 
alternatively from mannose by the action of hexokinase (HK). 
Thus, decreased Man-6-P production due to the MPI defi cien-
cy can be restored by the mannose supplementation therapy. 
Phosphomannomutase (PMM2) converts Man-6-P to Man-1
-P, but since MPI can also catabolizes Man-6-P, supplementary 
mannose treatment does not improve PMM2-CDG symptoms. 
Inhibition of MPI activity might provide more Man-6-P and thus 
overcome low residual activity of PMM2.
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SLC35C1-CDG (CDG-IIc)
Clinical symptoms of SLC35C1-CDG are the conse-
quences of the defect of GDP-fucose transporter 
and include immunodefi ciency caused by the ab-
sence of carbohydrate-based selectin ligands on 
the surface of neutrophils resulting in recurrent in-
fections with hyperleukocytosis as well as severe 
psychomotor and mental retardation. In some pa-
tients, increased level of fucose achieved by oral 
supplementation might overcome low affi  nity of 
the fucose transporters and in that way result in 
clinical improvements (85). However, the observa-
tions that fucose treatment did not have the eff ect 
in some other cases, suggest that the eff ectiveness 
of fucose therapy depends on the nature of the 
mutation (12).
PIGM-CDG
Constitutional mutation in the promoter of a 
housekeeping gene PIGM causes histone hy-
poacetylation and disruption of binding of SP1 
transcription factor, resulting in defi ciency of the 
fi rst mannosyltransferase in the GPI-anchor bio-
synthesis pathway and consequently low glyco-
sylphosphatidylinositol content (86). PIGM-CDG is 
characterized by splanchnic vein thrombosis and 
epilepsy. Treatment with a histone deacetylase in-
hibitor, butyrate, was proposed as an eff ective 
therapy for PIGM-CDG in vitro as well as in vivo, 
since it was shown to increase PIGM transcription 
and GPI expression, and is able to cause complete 
cessation of intractable seizures on one PIGM-CDG 
patient (87). It may be an eff ective therapeutic op-
tion for other diseases caused by Sp1-dependent 
hypoacetylation, so further investigations are 
needed.
Unfortunately, the successful therapy for PMM2-
CDG, the most prevalent CDG is not yet available, 
although many attempts to design the eff ective 
therapeutic approach have been undertaken. One 
of the examples is the application of cell perme-
able mannose-1-phosphate derivatives that suc-
ceeded to restore glycosylation to normal levels, 
but the half-life of these derivatives was too short 
(88). In addition, zaragozic acid A, a squalene syn-
thase inhibitor, was shown to be able to improve 
protein N-glycosylation, by redirecting the fl ow of 
the polyisoprene pathway toward dolichol by low-
ering cholesterol biosynthesis (89). As mentioned 
before, defi ciency of phosphomannomutase 2 
(PMM2) and mannosephospho isomerase (MPI-
CDG) reduces the metabolic fl ux of mannose-6-
phosphate (Man-6-P) (Figure 2), which results in 
impaired N-glycosylation. Both enzymes compete 
for the same substrate, Man-6-P. Mannose supple-
mentation reverses most of the symptoms of MPI-
CDG patients, but has no eff ect on PMM2-CDG pa-
tients because Man-6-P is catabolized by MPI. It 
was recently proposed that inhibition of MPI activ-
ity might provide more Man-6-P for glycosylation 
and possibly help PMM2-CDG patients with resid-
ual PMM2 activity (90). Application of a potent MPI 
inhibitor from the benzoisothiazolone series suc-
cessfully diverted Man-6-P towards glycosylation 
in various cell lines including fi broblasts from 
PMM2-CDG patients and improved N-glycosyla-
tion. Hopefully, this novel therapeutic approach 
will be also eff ective in clinical trials and benefi cial 
for at least a subset of PMM2-CDG patients.
Conclusions and remarks
Glycobiology is an emerging and one of the most 
promising fi elds of biomedicine. Many glycosyla-
tion pathways are not yet elucidated and numer-
ous glycan roles wait to be identifi ed. 250 gene 
products are recognized to be involved in glycosy-
lation pathways, thus it is reasonable to believe 
that in addition to 45 recognized CDGs many oth-
ers will be discovered. The biggest breakthrough 
is expected to be achieved in recognition of de-
fects of lipid glycosylation, dolichol synthesis, pro-
teoglycans, and organ-specifi c glycosylation path-
ways, but also in the fi eld of complex genetic dis-
orders where glycosylation is not the main focus 
of interest yet. Hopefully, enormous eff orts put in 
mouse models of CDGs will also provide new in-
sights and knowledge in the fi eld. Although be-
longing to the orphan (i.e. rare) diseases group, 
CDGs also represents a huge challenge for both 
pharmaceutical industry and scientists who are 
trying to understand complex synthetic pathways 
of glycosylation, the most complex modifi cations 
of proteins and lipids. In addition, the estimation 
of thousands undiscovered or misdiagnosed CDG 
patients alerts on the necessity of the improve-
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ment of clinical awareness of CDGs and develop-
ment of better biochemical and molecular diag-
nostics.
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Kompleksnost urođenih poremećaja glikozilacije
Sažetak
Šećerni dijelovi glikokonjugata utječu na mnoga biokemijska i biološka svojstva tih molekula. Glikozilacija, kovalentno pripajanje šećera (glikana) 
proteinima i lipidima vrlo je složen i visokokoordiniran proces koji uključuje više od 250 različitih genskih produkata. Nedostatak enzima i tran-
sportera uključenih u glikozilaciju ima za posljedicu nedostatnu ili nepravilnu glikozilaciju te dovodi do patoloških promjena mnogih fi zioloških 
procesa. Specifi čne mutacije gena čiji su proteinski produkti uključeni u glikozilaciju uzrokuju nastanak rijetkih, ali ozbiljnih bolesti – urođenih 
poremećaja glikozilacije (engl. congenital disorders of glycosylation, CDGs). Do danas je poznato 45 tipova CDGs. Kliničke manifestacije bolesti širo-
kog su raspona (od vrlo blagih do smrti), a zasad se samo tri tipa CDGs mogu donekle uspješno liječiti. Simptomi CDGs vrlo su raznoliki, a premda 
su neki uobičajeni za više tipova CDGs, s obzirom na to da se javljaju i kod drugih, nevezanih bolesti (posebice neuroloških), sumnja se da postoje 
brojni slučajevi CDG koji još nisu dijagnosticirani ili su pogrešno dijagnosticirani. Premda ne postoje specifi čni testovi za dijagnosticiranje CDGs, u 
tu se svrhu najčešće koriste glikanske analize serumskog transferina (izoelektričnim fokusiranjem ili sofi sticiranijim metodama kao što su HPLC 
(engl. high-performance liquid chromatography) i MALDI (engl. matrix-assisted laser desorption/ionization)) ili serumskih N-glikana (masenom 
spektrometrijom), analize enzimske aktivnosti i analize nukleotidnog slijeda DNA. U ovom preglednom članku predočene su trenutne spoznaje 
o kliničkim, biokemijskim i genetičkim osobinama pojedinih tipova CDGs, kao i postojeći dijagnostički i terapijski postupci, kako bi se proširila 
svijest o postojanju ovih rijetkih bolesti i potaknula nastojanja da se rasvijetli genetička osnova njihova nastanka, poboljša dijagnostika i razviju 
novi terapijski pristupi za njihovo liječenje.
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